Condition: Cancer of Rectum · Sponsor: Odense University Hospital
The purpose of this investigator-initiated, multicenter phase II trial is to evaluate the efficacy and tolerability of nivolumab and ipilimumab in patients with stage 1-3 MSI/dMMR rectal cancer. The primary objective is: Number of patients with complete clinical response after one or two cycles of immunotherapy. Patients will be treated with 1 or 2 cycles of combination immunotherapy: Cycle 1: Nivolumab 3 mg/kg days 1 and 15 \& ipilimumab 1 mg/kg day 1 Cycle 2: Nivolumab 3 mg/kg days 50 and 65 \& ipilimumab 1 mg/kg day 50
This description comes directly from the study's public registry record.
Julie Bach · 30714320 · Julie.Kristina.Bach@rsyd.dk
Christian P Olsen, Phd · 24342488 · Christian.pilely.olsen@rsyd.dk
Always discuss trial participation with your own doctor first.
| Aalborg University Hospital | Aalborg, Denmark | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Department of Oncology, Odense University Hospital | Odense, Denmark | Recruiting |
| Zealand University Hospital | Roskilde, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05732389